Syngene International, established in 1993 as a Biocon subsidiary, is India's first Contract Research Organization (CRO) which later expanded to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). The company serves as an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors.
The company's total research and manufacturing infrastructure is spread across 1.9 million square feet across locations. The operations are spread across 2 million sq. ft. with facilities at Bangalore, Hyderabad, and Mangalore. The company has a base of 6000+ scientists and has 400+ active customers with engagements with 13 out of the top 15 global pharma companies.
The company reported market capitalization of ₹25,957 Crore as of recent data, with revenue of ₹3,642 Crore and profit of ₹496 Crore. Sales rose 4.41% to ₹3,642.40 Crore in the year ended March 2025, as against ₹3,488.60 Crore during the previous year ended March 2024.
* Revenue: ₹1,018 Crore in Q4 FY25, marking a record and representing 11% increase compared to last year.
* Net profit: ₹183.3 Crore for Q4 FY25, up 2.8% from previous year.
* The company's board recommended a final dividend of ₹1.25 per equity share for the financial year 2024-25.
The company caters to diverse end-user industries like Pharmaceuticals, Animal Health, Agrochemicals, Consumer Packaged Goods, and Chemicals/Polymers. The company's services include discovery, development, manufacturing, SynVent Integrated Drug discovery, dedicated centers, and Center for Advanced Protein Studies (CAPS). Its discovery services span the entire spectrum of early-stage research from target identification to delivery of drug candidates for further development. It offers preclinical development, active pharmaceutical ingredient and drug product development for both small molecules and biologics.
The company holds 400+ patents jointly with clients and has built strong relationships with global pharmaceutical companies. Over the years leading up to 2021, Syngene International expanded its research collaboration with companies such as Abbott, Bristol Myers Squibb, Herbalife, and Glaxo Smith Kline.
Peter Bains has been appointed as the full-time CEO & Managing Director, stepping down from his role as Group CEO of Biocon effective April 1, 2025. Peter has over three decades of experience in the pharmaceutical and biotechnology sectors. At Syngene, he is responsible for strategy and execution, steering the investment decisions, leading the executive team, and the Company's business operations.
The company's Chairperson is Kiran Mazumdar Shaw, a renowned biotechnology entrepreneur. Ms. Shaw is a first-generation entrepreneur with over 45 years of experience in the field of biotechnology.
Syngene has converted many pilot projects into full contracts and acquired a state-of-the-art biologics manufacturing facility in the US, expecting early teens revenue growth for FY26. The company has been expanding its capabilities in biologics manufacturing and has successfully completed regulatory inspections with zero observations.
A recent inspection concluded successfully, with the facility found to be in compliance with the required regulations. The inspection resulted in zero observations and no Form 483 was issued. The inspection has been classified as 'no action indicated' (NAI).
The company expects revenue growth in fiscal year 2025 to be in the range of high single digits to low double digits with momentum building up during the year. The company expects the EBITDA margin to be similar to the level delivered in fiscal year 2024 and PAT growth in single digits.
The current industry dynamics, particularly the geopolitical shifts, present a substantial opportunity for the organization. The company continues to generate strong cash flows and maintains a robust balance sheet. They are investing in technology and capabilities that will position them favorably to leverage the opportunity and capture an increased market share.
Promoter holding stands at 52.7% as of recent data, indicating strong promoter commitment to the business. Promoter holding in Syngene International Ltd has gone down to 52.73% as of March 2025 from 54.72% as of June 2024.
Syngene International continues to strengthen its position as a leading contract research, development, and manufacturing organization, leveraging its scientific expertise and global partnerships to serve the evolving needs of the pharmaceutical and biotechnology industries worldwide.
